title: Optimization of pyrrolidinone based HIV protease inhibitors.
abstract: Optimization of P1-substituted pyrrolidinone based HIV protease inhibitors has yielded analogs with very potent antiviral activity.
authors.affiliation: GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA. ron.g.sherrill@gsk.com
authors.forename: Ronald G
authors.initials: RG
authors.lastname: Sherrill
authors.forename: C Webster
authors.initials: CW
authors.lastname: Andrews
authors.forename: William J
authors.initials: WJ
authors.lastname: Bock
authors.forename: Ronda G
authors.initials: RG
authors.lastname: Davis-Ward
authors.forename: Eric S
authors.initials: ES
authors.lastname: Furfine
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Hazen
authors.forename: Randy D
authors.initials: RD
authors.lastname: Rutkowske
authors.forename: Andrew
authors.initials: A
authors.lastname: Spaltenstein
authors.forename: Lois L
authors.initials: LL
authors.lastname: Wright
mesh_terms: D017320:HIV Protease Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D008958:Models, Molecular; D011760:Pyrrolidinones / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D017320:HIV Protease Inhibitors; D011760:Pyrrolidinones